Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 468.9 Billion KRW | -5.88% |
| 2022 | 498.18 Billion KRW | 0.79% |
| 2021 | 494.27 Billion KRW | 12.56% |
| 2020 | 439.11 Billion KRW | 0.38% |
| 2019 | 437.45 Billion KRW | 1.2% |
| 2018 | 432.25 Billion KRW | -0.94% |
| 2017 | 436.37 Billion KRW | 1.19% |
| 2016 | 431.26 Billion KRW | -0.08% |
| 2015 | 431.62 Billion KRW | 0.18% |
| 2014 | 430.83 Billion KRW | 8.14% |
| 2013 | 398.38 Billion KRW | 5.49% |
| 2012 | 377.66 Billion KRW | 4.69% |
| 2011 | 360.75 Billion KRW | 14.33% |
| 2010 | 315.55 Billion KRW | 8.86% |
| 2009 | 289.86 Billion KRW | 8.44% |
| 2008 | 267.29 Billion KRW | 52.69% |
| 2007 | 175.05 Billion KRW | 10.42% |
| 2006 | 158.54 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 503.94 Billion KRW | 4.72% |
| 2024 Q1 | 481.23 Billion KRW | 2.63% |
| 2023 FY | 468.9 Billion KRW | -5.88% |
| 2023 Q4 | 468.9 Billion KRW | -4.15% |
| 2023 Q3 | 489.22 Billion KRW | 6.09% |
| 2023 Q2 | 461.12 Billion KRW | 3.5% |
| 2023 Q1 | 445.53 Billion KRW | -10.57% |
| 2022 Q4 | 498.18 Billion KRW | -2.29% |
| 2022 Q3 | 509.88 Billion KRW | 4.99% |
| 2022 FY | 498.18 Billion KRW | 0.79% |
| 2022 Q1 | 475.74 Billion KRW | -3.75% |
| 2022 Q2 | 485.66 Billion KRW | 2.09% |
| 2021 Q4 | 494.27 Billion KRW | 3.2% |
| 2021 Q1 | 452.8 Billion KRW | 3.12% |
| 2021 Q2 | 448.72 Billion KRW | -0.9% |
| 2021 Q3 | 478.92 Billion KRW | 6.73% |
| 2021 FY | 494.27 Billion KRW | 12.56% |
| 2020 Q4 | 439.11 Billion KRW | -6.35% |
| 2020 Q1 | 440.48 Billion KRW | 0.69% |
| 2020 Q3 | 468.9 Billion KRW | 4.23% |
| 2020 FY | 439.11 Billion KRW | 0.38% |
| 2020 Q2 | 449.89 Billion KRW | 2.14% |
| 2019 Q2 | 442.69 Billion KRW | 0.19% |
| 2019 FY | 437.45 Billion KRW | 1.2% |
| 2019 Q4 | 437.45 Billion KRW | -2.22% |
| 2019 Q3 | 447.4 Billion KRW | 1.06% |
| 2019 Q1 | 441.84 Billion KRW | 2.22% |
| 2018 Q3 | 448.53 Billion KRW | 1.83% |
| 2018 Q4 | 432.25 Billion KRW | -3.63% |
| 2018 FY | 432.25 Billion KRW | -0.94% |
| 2018 Q1 | 443.26 Billion KRW | 1.58% |
| 2018 Q2 | 440.46 Billion KRW | -0.63% |
| 2017 FY | 436.37 Billion KRW | 1.19% |
| 2017 Q3 | 450.91 Billion KRW | 2.68% |
| 2017 Q2 | 439.16 Billion KRW | 1.08% |
| 2017 Q1 | 434.47 Billion KRW | 0.74% |
| 2017 Q4 | 436.37 Billion KRW | -3.22% |
| 2016 Q1 | 434.27 Billion KRW | 0.0% |
| 2016 Q3 | 443.28 Billion KRW | 1.22% |
| 2016 Q2 | 437.91 Billion KRW | 0.84% |
| 2016 FY | 431.26 Billion KRW | -0.08% |
| 2016 Q4 | 431.26 Billion KRW | -2.71% |
| 2015 FY | 431.62 Billion KRW | 0.18% |
| 2015 Q3 | 437.04 Billion KRW | 1.96% |
| 2015 Q2 | 428.62 Billion KRW | -0.51% |
| 2015 Q1 | 430.83 Billion KRW | 1.6% |
| 2014 FY | 430.83 Billion KRW | 8.14% |
| 2014 Q2 | 435.64 Billion KRW | 9.35% |
| 2014 Q4 | 424.06 Billion KRW | -3.46% |
| 2014 Q3 | 439.24 Billion KRW | 0.83% |
| 2014 Q1 | 398.38 Billion KRW | 0.0% |
| 2013 FY | 398.38 Billion KRW | 5.49% |
| 2013 Q1 | 377.66 Billion KRW | 1.27% |
| 2012 Q4 | 372.92 Billion KRW | 0.72% |
| 2012 Q3 | 370.25 Billion KRW | 2.03% |
| 2012 Q1 | 360.75 Billion KRW | 0.08% |
| 2012 FY | 377.66 Billion KRW | 4.69% |
| 2012 Q2 | 362.9 Billion KRW | 0.59% |
| 2011 Q2 | 331.38 Billion KRW | 5.02% |
| 2011 FY | 360.75 Billion KRW | 14.33% |
| 2011 Q1 | 315.55 Billion KRW | 4.5% |
| 2011 Q3 | 352.41 Billion KRW | 6.35% |
| 2011 Q4 | 360.45 Billion KRW | 2.28% |
| 2010 Q3 | 287.14 Billion KRW | -1.37% |
| 2010 Q4 | 301.95 Billion KRW | 5.16% |
| 2010 Q2 | 291.11 Billion KRW | 0.0% |
| 2010 FY | 315.55 Billion KRW | 8.86% |
| 2009 Q1 | 267.29 Billion KRW | 35.3% |
| 2009 FY | 289.86 Billion KRW | 8.44% |
| 2009 Q4 | 290.45 Billion KRW | 12.35% |
| 2009 Q3 | 258.52 Billion KRW | -3.67% |
| 2009 Q2 | 268.38 Billion KRW | 0.41% |
| 2008 Q2 | 190.17 Billion KRW | 8.63% |
| 2008 Q1 | 175.05 Billion KRW | 7.4% |
| 2008 Q4 | 197.54 Billion KRW | -11.03% |
| 2008 Q3 | 222.03 Billion KRW | 16.75% |
| 2008 FY | 267.29 Billion KRW | 52.69% |
| 2007 Q3 | 166.36 Billion KRW | -8.53% |
| 2007 FY | 175.05 Billion KRW | 10.42% |
| 2007 Q4 | 162.99 Billion KRW | -2.03% |
| 2007 Q2 | 181.87 Billion KRW | 0.0% |
| 2006 FY | 158.54 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.565% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 76.041% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 46.533% |
| HANDOK Inc. | 790.33 Billion KRW | 40.671% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -174.823% |
| Yuhan Corporation | 2814.07 Billion KRW | 83.337% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 64.348% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -401.613% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 75.979% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -95.582% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -307.837% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -98.227% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -34.593% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.565% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -11.859% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 6.177% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 20.444% |
| JW Holdings Corporation | 1176.26 Billion KRW | 60.136% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 23.289% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 66.565% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.306% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -33.94% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -204.401% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -26.498% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 3.78% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -136.565% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 56.505% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 73.513% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.306% |
| Yuhan Corporation | 2814.07 Billion KRW | 83.337% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 46.715% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -106.929% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 52.814% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 27.306% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -11.67% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -0.009% |
| CKD Bio Corp. | 293.78 Billion KRW | -59.608% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 7.696% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 17.004% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -16.867% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -33.94% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 67.795% |
| Boryung Corporation | 922.36 Billion KRW | 49.163% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -5.976% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 0.0% |
| JW Lifescience Corporation | 255.83 Billion KRW | -83.282% |